Daniele Ferrari

Dr. Daniele Ferrari

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2023 in Aging Cell
Verified
Journal Article
Open access
OCOzmen Cobanoglu
Ozmen Cobanoglu
LDLou Delval
Lou Delval
DFDaniele Ferrari
Daniele Ferrari
LDLucie Deruyter
Lucie Deruyter
SHSéverine Heumel
Séverine Heumel
FTFrançois Trottein
François Trottein
The age‐related decline in immunity reduces the effectiveness of vaccines in older adults. Immunosenescence is associated with chronic, low‐grade inflammation, and the accumulation of senescent cells. The latter express Bcl‐2 family members (providing resistance to cell death) and exhibit a pro‐inflammatory, senescence‐associated secretory phenotype (SASP). Preexisting senescent cells cause many aging‐related disorders and therapeutic means of eliminating these cells have recently gained attention. The potential consequences of senescent cell removal on vaccine efficacy in older individuals are still ignored. We used the Bcl‐2 family inhibitor ABT‐263 to investigate the effects of pre‐vaccination senolysis on immune responses in old mice. Two different ovalbumin (OVA)‐containing vaccines (containing a saponin‐based or a CpG oligodeoxynucleotide adjuvant) were tested. ABT‐263 depleted senescent cells (apoptosis) and ablated the basal and lipopolysaccharide‐induced production of SASP‐related factors in old mice. Depletion of senescent cells prior to vaccination (prime/boost) had little effect on OVA‐specific antibody and T‐cell responses (slightly reduced and augmented, respectively). We then used a preclinical melanoma model to test the antitumor potential of senolysis before vaccination (prime with the vaccine and OVA boost by tumor cells). Surprisingly, ABT‐263 treatment abrogated the vaccine's ability to protect against B16 melanoma growth in old animals, an effect associated with reduced antigen‐specific T‐cell responses. Some, but not all, of the effects were age‐specific, which suggests that preexisting senescent cells were partly involved. Hence, depletion of senescent cells modifies immune responses to vaccines in some settings and caution should be taken when incorporating senolytics into vaccine‐based cancer therapies.

14 March 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
DFDaniele Ferrari
Daniele Ferrari
ÖÇÖzmen Çobanoglu
Özmen Çobanoglu
SSSana Sayedipour
Sana Sayedipour
OLOmar Luna
Omar Luna
SFSonia Angela Marlies Ferkel
Sonia Angela Marlies Ferkel
FRFernanda Ramos-Gomes
Fernanda Ramos-Gomes
Background/Objectives: Immunotherapy has shown promising results in some cancers, but its efficacy remains limited in pancreatic ductal adenocarcinoma (PDAC). Vaccines in nanoparticle form (nanovaccines) can incorporate immunostimulating components to induce a potent immune response. As mesothelin (MSLN) is a tumor-associated antigen overexpressed in PDAC, we evaluated the effect of MSLN nanovaccine in a syngeneic orthotopic KPC-PDAC mouse model. Methods: An MSLN peptide combining three MSLN epitopes and two adjuvants, poly I:C and R848, was encapsulated in PLGA–chitosan nanoparticles to generate the nanovaccine. Results: The MSLN nanovaccine was successfully taken up by dendritic cells in vitro and was found in inguinal lymph nodes 24 h after subcutaneous injection into C57BL/6 mice. Nanovaccine re-stimulation of splenocytes from vaccinated mice led to increased levels of interferon-γ in vitro compared to unstimulated splenocytes. Higher levels of MSLN-specific IgM and IgG antibodies were detected in the serum of vaccinated mice compared to that of control mice. Three vaccination regimens were tested: a prophylactic scheme that included vaccination before tumor induction and two therapeutic schemes involving early and late vaccination after tumor cell inoculation. MSLN nanovaccination inhibited KPC tumor progression and metastasis and induced higher CD8+ T cell infiltration in the tumor that developed in response to prophylactic and early therapeutic schedules but not in response to a later vaccination approach. Although the nanovaccine treatment elicited higher humoral and cellular antigen-specific responses in tumor-bearing mice for both vaccination strategies, the therapeutic vaccination also increased the expression of exhaustion markers in CD8+ T cells. Conclusions: Our results support the relevance of an MSLN-based nanovaccine as a new immunotherapy treatment for PDAC and propose an innovative method of vaccine delivery using NPs.

1 November 2021 in Brain Research Bulletin
Verified
Journal Article
Closed access
GNGlauce Crivelaro Nascimento
Glauce Crivelaro Nascimento
BPBruna Balbino de Paula
Bruna Balbino de Paula
DFDaniele Ferrari
Daniele Ferrari
DIDaniela Mizusaki Iyomasa
Daniela Mizusaki Iyomasa
YPYamba C.L. Pereira
Yamba C.L. Pereira
EDElaine Del-Bel
Elaine Del-Bel

23 September 2026 in Matrix Biology
Verified
Journal Article
Open access
AAAlexandre Aubert
Alexandre Aubert
APAnna Prudova
Anna Prudova
JTJeffrey S. Tang
Jeffrey S. Tang
JSJhunam Sidhu
Jhunam Sidhu
HAHans H. Adomat
Hans H. Adomat
DGDavid James Granville
David James Granville